Encompass Health Co. (NYSE:EHC) Shares Sold by Equitable Trust Co.

Equitable Trust Co. trimmed its position in Encompass Health Co. (NYSE:EHC) by 8.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,329 shares of the company’s stock after selling 500 shares during the period. Equitable Trust Co.’s holdings in Encompass Health were worth $492,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. State Street Corp increased its stake in shares of Encompass Health by 0.7% in the third quarter. State Street Corp now owns 3,025,769 shares of the company’s stock worth $292,410,000 after acquiring an additional 21,329 shares during the period. Geode Capital Management LLC grew its position in Encompass Health by 1.2% during the 3rd quarter. Geode Capital Management LLC now owns 1,673,610 shares of the company’s stock worth $161,781,000 after purchasing an additional 20,547 shares during the period. Copeland Capital Management LLC lifted its holdings in shares of Encompass Health by 0.7% in the 4th quarter. Copeland Capital Management LLC now owns 1,293,098 shares of the company’s stock valued at $119,418,000 after buying an additional 8,548 shares during the period. Point72 Asset Management L.P. boosted its stake in shares of Encompass Health by 2,458.5% in the third quarter. Point72 Asset Management L.P. now owns 869,104 shares of the company’s stock worth $83,990,000 after buying an additional 835,135 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. grew its holdings in Encompass Health by 0.4% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 769,716 shares of the company’s stock worth $71,083,000 after acquiring an additional 2,904 shares during the period. Hedge funds and other institutional investors own 97.25% of the company’s stock.

Encompass Health Price Performance

NYSE:EHC opened at $99.37 on Wednesday. The stock has a 50 day moving average of $96.14 and a two-hundred day moving average of $95.41. Encompass Health Co. has a 12 month low of $72.38 and a 12 month high of $104.55. The firm has a market cap of $10.01 billion, a P/E ratio of 22.28, a price-to-earnings-growth ratio of 1.18 and a beta of 0.90. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.88.

Encompass Health (NYSE:EHC) last issued its quarterly earnings results on Thursday, February 6th. The company reported $1.17 EPS for the quarter, topping the consensus estimate of $1.05 by $0.12. Encompass Health had a return on equity of 18.06% and a net margin of 8.48%. On average, analysts expect that Encompass Health Co. will post 4.76 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have commented on EHC. StockNews.com lowered Encompass Health from a “buy” rating to a “hold” rating in a research report on Friday, February 7th. Truist Financial reissued a “buy” rating and set a $116.00 price target (up from $108.00) on shares of Encompass Health in a report on Wednesday, October 30th. KeyCorp lifted their price objective on shares of Encompass Health from $117.00 to $120.00 and gave the company an “overweight” rating in a report on Monday. Barclays increased their target price on shares of Encompass Health from $116.00 to $118.00 and gave the stock an “overweight” rating in a research note on Friday, February 7th. Finally, William Blair restated an “outperform” rating on shares of Encompass Health in a research note on Friday, February 7th. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $107.67.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.